Skip to main content

Table 1 Clinical characteristics of primary Sjogren’s syndrome patients

From: Olfactory impairment in patients with primary Sjogren’s syndrome and its correlation with organ involvement and immunological abnormalities

  Patients Controls
(n = 52) (100%) (n = 52) (100%)
Age (years) 47.36 ± 12.45 49.09 ± 11.48
Sex (female) 49 (94.23%) 48 (92.31%)
Duration of disease (years) 4.53 ± 4.64 NA
Education (years) 9.32 ± 4.91 11.05 ± 5.37
Smoking 0 0
Objective ocular involvement 45 (86.54%)  
Objective oral involvement 40 (76.92%)  
Positive salivary gland biopsy 39 (75%)  
ESR (mm after 1 h) 34.38 ± 21.39  
CRP (mg/L) 11.95 ± 10.36  
ANA 43 (82.69%)  
Anti-SSA antibody 41 (78.84%)  
Anti-SSB antibody 15 (28.85%)  
RF 13 (25%)  
Current treatment
 Corticosteroids 40 (76.92%)  
 Hydroxychloroquine 32 (61.54%)  
 Cyclophosphamide 10 (19.23%)  
 Cyclosporine 12 (23.07%)  
 Methotrexate 2 (3.85%)  
 Mycophenolate mofetil 4 (7.69%)  
Tripterygium wilfordii 6 (11.54%)  
 Other immunosuppressant agent 2 (3.85%)  
Disease activity indexes
 ESSPRI 3.14 ± 1.63  
 ESSDRI 9.17 ± 6.08  
  1. Results are expressed as mean ± SD or number (%). ESR, erythrocyte sedimentation rate, CRP C-reactive protein, ANA antinuclear antibody, RF rheumatoid factor, ESSDAI EULAR SS disease activity index, ESSPRI EULAR SS patient reported index